Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Biodesix, Inc. has received a consensus rating of "Moderate Buy" from six analysts, with an average 1-year target price of $32.50.
• Insider activity shows significant confidence as Director Jack W. Schuler purchased 142,045 shares for nearly $1 million, increasing his stake in the company.
• Despite posting a revenue of $20.02 million in their last earnings report, Biodesix missed earnings per share estimates with a reported loss of ($1.60).

Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $32.50.

Several equities research analysts have commented on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Biodesix in a research note on Saturday, September 27th. Canaccord Genuity Group set a $20.00 price objective on Biodesix and gave the stock a "buy" rating in a research note on Friday, September 19th. Finally, Wall Street Zen upgraded Biodesix to a "sell" rating in a research note on Saturday, September 13th.

Insider Activity

In related news, Director Jack W. Schuler acquired 142,045 shares of the company's stock in a transaction dated Friday, September 19th. The shares were bought at an average price of $7.04 per share, for a total transaction of $999,996.80. Following the purchase, the director directly owned 1,380,745 shares in the company, valued at approximately $9,720,444.80. This trade represents a 11.47% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 334,836 shares of company stock worth $2,611,362 and sold 293 shares worth $2,461. 30.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. XTX Topco Ltd grew its holdings in Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after buying an additional 102,494 shares in the last quarter. Blair William & Co. IL lifted its position in shares of Biodesix by 33.3% during the 1st quarter. Blair William & Co. IL now owns 124,100 shares of the company's stock worth $78,000 after buying an additional 31,000 shares during the last quarter. Millennium Management LLC raised its position in Biodesix by 20.2% in the fourth quarter. Millennium Management LLC now owns 198,671 shares of the company's stock valued at $304,000 after purchasing an additional 33,329 shares during the last quarter. Monashee Investment Management LLC increased its stake in shares of Biodesix by 15.7% in the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company's stock valued at $2,532,000 after buying an additional 549,121 shares during the period. Finally, Birchview Capital LP increased its stake in shares of Biodesix by 2.8% in the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company's stock valued at $3,586,000 after buying an additional 154,937 shares during the period. 20.96% of the stock is owned by institutional investors and hedge funds.

Biodesix Price Performance

Shares of BDSX stock opened at $7.30 on Wednesday. The firm has a market cap of $53.51 million, a price-to-earnings ratio of -1.26 and a beta of 0.98. Biodesix has a 12 month low of $3.44 and a 12 month high of $34.40. The stock has a 50-day moving average price of $8.10 and a 200 day moving average price of $8.19. The company has a quick ratio of 2.14, a current ratio of 2.14 and a debt-to-equity ratio of 41.11.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by ($0.20). Biodesix had a negative net margin of 53.66% and a negative return on equity of 269.67%. The business had revenue of $20.02 million during the quarter, compared to analyst estimates of $18.47 million. Biodesix has set its FY 2025 guidance at EPS. Research analysts expect that Biodesix will post -0.35 EPS for the current year.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.